Adult Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial
Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification,
including cytogenetics. We want to study at diagnosis several blast cells parameters on
frozen samples of GRAALL protocols enrolled patients:
1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each
blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by
Western Blot analysis.
The comparison between these parameters, and main haematological data, will be followed by a
prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete
remission, and survival.
Combination of the studied parameters will allow to appreciate a clonal diversity. This will
help to predict, at diagnosis, high probability of resistance to treatment.
n/a
Observational Model: Defined Population, Time Perspective: Longitudinal
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03419494 -
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
|
N/A | |
| Recruiting |
NCT02072785 -
Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
|
Phase 3 | |
| Completed |
NCT01484015 -
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
|
Phase 1 | |
| Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
| Completed |
NCT00537030 -
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
|
N/A | |
| Active, not recruiting |
NCT02159495 -
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
|
Phase 1 | |
| Completed |
NCT01251575 -
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
|
Phase 2 |